Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 83

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Increased miR-223 expression in T cells from patients with rheumatoid arthritis leads to decreased insulin-like growth factor-1-mediated interleukin-10 production

Lu, M-C, Yu, C-L, Chen, H-C, Yu, H-C, Huang, H-B, Lai, N-S·2014·Clinical and Experimental Immunology

Abstract

Summary: We hypothesized that the aberrant expression of microRNAs (miRNAs) in rheumatoid arthritis (RA) T cells was involved in the pathogenesis of RA. The expression profile of 270 human miRNAs in T cells from the first five RA patients and five controls were analysed by real-time polymerase chain reaction. Twelve miRNAs exhibited potentially aberrant expression in RA T cells compared to normal T cells. After validation with another 22 RA patients and 19 controls, miR-223 and miR-34b were over-expressed in RA T cells. The expression levels of miR-223 were correlated positively with the titre of rheumatoid factor (RF) in RA patients. Transfection of Jurkat cells with miR-223 mimic suppressed insulin-like growth factor-1 receptor (IGF-1R) and transfection with miR-34b mimic suppressed cAMP response element binding protein (CREB) protein expression by Western blotting. The protein expression of IGF-1R but not CREB was decreased in RA T cells. The addition of recombinant IGF-1-stimulated interleukin (IL)-10 production by activated normal T cells, but not RA T cells. The transfection of miR-223 mimic impaired IGF-1-mediated IL-10 production in activated normal T cells. The expression levels of SCD5, targeted by miR-34b, were decreased in RA T cells after microarray analysis. In conclusion, both miR-223 and miR-34b were over-expressed in RA T cells, but only the miR-223 expression levels were correlated positively with RF titre in RA patients. Functionally, the increased miR-223 expression could impair the IGF-1-mediated IL-10 production in activated RA T cells in vivo, which might contribute to the imbalance between proinflammatory and anti-inflammatory cytokines.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cei.12374

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 47

  1. Cooles, 2011, Pathophysiology of rheumatoid arthritis, Curr Opin Rheumatol, 23, 233, 10.1097/BOR.0b013e32834518a3 · DOI · Paper page
  2. Isaacs, 2008, Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future, Rheumatology (Oxf), 47, 1461, 10.1093/rheumatology/ken163 · DOI
  3. Goronzy, 2009, Developments in the scientific understanding of rheumatoid arthritis, Arthritis Res Ther, 11, 249, 10.1186/ar2758 · DOI
  4. Pratt, 2012, A CD4 T cell gene signature for early rheumatoid arthritis implicates interleukin 6-mediated STAT3 signalling, particularly in anti-citrullinated peptide antibody-negative disease, Ann Rheum Dis, 71, 1374, 10.1136/annrheumdis-2011-200968 · DOI
  5. Kremer, 2003, Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig, N Engl J Med, 349, 1907, 10.1056/NEJMoa035075 · DOI · Paper page
  6. Pauley, 2009, MicroRNA in autoimmunity and autoimmune diseases, J Autoimmun, 32, 189, 10.1016/j.jaut.2009.02.012 · DOI · Paper page
  7. Kurowska-Stolarska, 2011, MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis, Proc Natl Acad Sci USA, 108, 11193, 10.1073/pnas.1019536108 · DOI · Paper page
  8. Semaan, 2011, miR-346 controls release of TNF-alpha protein and stability of its mRNA in rheumatoid arthritis via tristetraprolin stabilization, PLOS ONE, 6, e19827, 10.1371/journal.pone.0019827 · DOI
  9. Pauley, 2008, Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients, Arthritis Res Ther, 10, R101, 10.1186/ar2493 · DOI · Paper page
  10. Zhu, 2012, The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-alpha, Nat Med, 18, 1077, 10.1038/nm.2815 · DOI · Paper page
  11. Stanczyk, 2011, Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation, Arthritis Rheum, 63, 373, 10.1002/art.30115 · DOI · Paper page
  12. Nakasa, 2008, Expression of microRNA-146 in rheumatoid arthritis synovial tissue, Arthritis Rheum, 58, 1284, 10.1002/art.23429 · DOI · Paper page
  13. Stanczyk, 2008, Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis, Arthritis Rheum, 58, 1001, 10.1002/art.23386 · DOI · Paper page
  14. Fulci, 2010, miR-223 is overexpressed in T-lymphocytes of patients affected by rheumatoid arthritis, Hum Immunol, 71, 206, 10.1016/j.humimm.2009.11.008 · DOI · Paper page
  15. Arnett, 1988, The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis, Arthritis Rheum, 31, 315, 10.1002/art.1780310302 · DOI · Paper page
  16. Chen, 2005, Real-time quantification of microRNAs by stem-loop RT–PCR, Nucleic Acids Res, 33, e179, 10.1093/nar/gni178 · DOI · Paper page
  17. Lai, 2013, Aberrant expression of microRNAs in T cells from patients with ankylosing spondylitis contributes to the immunopathogenesis, Clin Exp Immunol, 173, 47, 10.1111/cei.12089 · DOI
  18. Lu, 2013, Decreased microRNA(miR)-145 and increased miR-224 expression in T cells from patients with systemic lupus erythematosus involved in lupus immunopathogenesis, Clin Exp Immunol, 171, 91, 10.1111/j.1365-2249.2012.04676.x · DOI
  19. Jordan, 2008, Optimizing electroporation conditions in primary and other difficult-to-transfect cells, J Biomol Tech, 19, 328
  20. Jia, 2011, MiR-223 suppresses cell proliferation by targeting IGF-1R, PLOS ONE, 6, e27008, 10.1371/journal.pone.0027008 · DOI
  21. Pigazzi, 2009, miR-34b targets cyclic AMP-responsive element binding protein in acute myeloid leukemia, Cancer Res, 69, 2471, 10.1158/0008-5472.CAN-08-3404 · DOI
  22. Kooijman, 2004, Insulin-like growth factor-I stimulates IL-10 production in human T cells, J Leukoc Biol, 76, 862, 10.1189/jlb.0404248 · DOI
  23. Li, 2010, Altered microRNA expression profile with miR-146a upregulation in CD4+ T cells from patients with rheumatoid arthritis, Arthritis Res Ther, 12, R81, 10.1186/ar3006 · DOI · Paper page
  24. Niimoto, 2010, MicroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients, BMC Musculoskelet Disord, 11, 209, 10.1186/1471-2474-11-209 · DOI · Paper page
  25. Sebastiani, 2011, Over-expression of miR-223 in T-lymphocytes of early rheumatoid arthritis patients, Clin Exp Rheumatol, 29, 1058
  26. Filková, 2013, Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis, Ann Rheum Dis, 10.1136/annrheumdis-2012-202815 · DOI · Paper page
  27. Murata, 2010, Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis, Arthritis Res Ther, 12, R86, 10.1186/ar3013 · DOI · Paper page
  28. Pandis, 2012, Identification of microRNA-221/222 and microRNA-323-3p association with rheumatoid arthritis via predictions using the human tumour necrosis factor transgenic mouse model, Ann Rheum Dis, 71, 1716, 10.1136/annrheumdis-2011-200803 · DOI
  29. Shibuya, 2013, Overexpression of microRNA-223 in rheumatoid arthritis synovium controls osteoclast differentiation, Mod Rheumatol, 23, 674, 10.3109/s10165-012-0710-1 · doi:10.3109/s10165-012-0710-1
  30. Sugatani, 2007, MicroRNA-223 is a key factor in osteoclast differentiation, J Cell Biochem, 101, 996, 10.1002/jcb.21335 · DOI · Paper page
  31. Li, 2012, Brief report: amelioration of collagen-induced arthritis in mice by lentivirus-mediated silencing of microRNA-223, Arthritis Rheum, 64, 3240, 10.1002/art.34550 · DOI
  32. Engvall, 2008, Cachexia in rheumatoid arthritis is associated with inflammatory activity, physical disability, and low bioavailable insulin-like growth factor, Scand J Rheumatol, 37, 321, 10.1080/03009740802055984 · DOI
  33. Lemmey, 2001, Association between insulin-like growth factor status and physical activity levels in rheumatoid arthritis, J Rheumatol, 28, 29
  34. Neidel, 2001, Changes in systemic levels of insulin-like growth factors and their binding proteins in patients with rheumatoid arthritis, Clin Exp Rheumatol, 19, 81
  35. Dhaunsi, 2012, Insulin-like growth factor-1 gene polymorphism in rheumatoid arthritis patients, Scand J Rheumatol, 41, 421, 10.3109/03009742.2012.691177 · DOI
  36. Laurberg, 2012, Insulin-like growth factor I receptor density on CD4+T-lymphocytes from active early steroid- and DMARD-naive rheumatoid arthritis patients is up-regulated and not influenced by 1 year of clinically effective treatment, Rheumatol Int, 32, 501, 10.1007/s00296-010-1683-z · DOI
  37. Boström, 2011, Resistin and insulin/insulin-like growth factor signaling in rheumatoid arthritis, Arthritis Rheum, 63, 2894, 10.1002/art.30527 · DOI
  38. Friedrich, 2008, Reference ranges of serum IGF-1 and IGFBP-3 levels in a general adult population: results of the Study of Health in Pomerania (SHIP), Growth Horm IGF Res, 18, 228, 10.1016/j.ghir.2007.09.005 · DOI
  39. Katsikis, 1994, Immunoregulatory role of interleukin 10 in rheumatoid arthritis, J Exp Med, 179, 1517, 10.1084/jem.179.5.1517 · DOI · Paper page
  40. O'Shea, 2002, Cytokines and autoimmunity, Nat Rev Immunol, 2, 37, 10.1038/nri702 · DOI · Paper page
  41. Joosten, 1997, Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction, Arthritis Rheum, 40, 249, 10.1002/art.1780400209 · DOI · Paper page
  42. Heo, 2010, IL-10 suppresses Th17 cells and promotes regulatory T cells in the CD4+ T cell population of rheumatoid arthritis patients, Immunol Lett, 127, 150, 10.1016/j.imlet.2009.10.006 · DOI
  43. Schenten, 2014, Signaling through the adaptor molecule MyD88 in CD4+ T cells is required to overcome suppression by regulatory T cells, Immunity, 40, 78, 10.1016/j.immuni.2013.10.023 · DOI
  44. Croft, 2014, The TNF family in T cell differentiation and function – unanswered questions and future directions, Semin Immunol, 10.1016/j.smim.2014.02.005 · DOI
  45. Wakisaka, 1998, Involvement of simultaneous multiple transcription factor expression, including cAMP responsive element binding protein and OCT-1, for synovial cell outgrowth in patients with rheumatoid arthritis, Ann Rheum Dis, 57, 487, 10.1136/ard.57.8.487 · doi:10.1136/ard.57.8.487
  46. Kotla, 2013, The transcription factor CREB enhances interleukin-17A production and inflammation in a mouse model of atherosclerosis, Sci Signal, 6, ra83, 10.1126/scisignal.2004214 · DOI
  47. Sinner, 2012, StearoylCoA desaturase-5: a novel regulator of neuronal cell proliferation and differentiation, PLOS ONE, 7, e39787, 10.1371/journal.pone.0039787 · DOI

Cited by

See all 83

Metadata

Authors
Lu, M.-C., Yu, C.-L., Chen, H.-C., Yu, H.-C., Huang, H.-B., & Lai, N.-S.
Affiliations
  • Division of Allergy, Immunology, and Rheumatology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan
  • Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
  • Department of Biomedical Sciences, Chang Gung University, Taoyuan, Taiwan
  • Department of Life Science and Institute of Molecular Biology, National Chung Cheng University, Chiayi, Taiwan
Venue
Clinical and Experimental Immunology
Published
2014-07-24
Volume
177
Issue
3
Pages
641-651
ISSN
  • 0009-9104
  • 1365-2249
Cited by
83
References
5
Language
en
Funders
  • National Science Council (101-2314-B-303-028-MY3)
  • Dalin Tzu Chi Hospital (DTCRD101-I-07)
  • Buddhist Tzu Chi Medical Foundation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.